1) Financial Performance Overview
- DuPont reported Q1 2026 net sales of $1.7 billion, a 4% YoY increase, driven by 2% organic growth and a 2% currency benefit.
- Adjusted EPS rose 53% YoY to $0.55, with a pro forma increase of 20%.
- Operating EBITDA was $414 million, up 15% YoY, resulting in a margin of 24.6%, an increase of 230 basis points.
- Free cash flow generation was $147 million, with a conversion rate of 65%.

2) Segment Performance Insights
- Healthcare & Water Technologies: Net sales of $806 million, up 6% YoY. Organic growth was 3%, with strong performance in medical packaging and biopharma.
- Diversified Industrials: Net sales of $875 million, a 3% increase YoY. Organic sales growth was flat, with strength in aerospace offset by declines in construction.
- Both segments showed improvements in operating EBITDA margins, with Healthcare & Water at 30.3% and Diversified Industrials at 22.9%.

3) Strategic Initiatives and Operational Improvements
- DuPont completed the divestiture of the Aramids business, enhancing focus on core operations.
- The company is advancing its 2035 sustainability goals, emphasizing sustainable innovation and operational excellence.
- The implementation of the 80/20 strategy is ongoing, targeting margin improvements without significant top-line impact.
- Investments in digital and AI capabilities are enhancing operational efficiency and productivity.

4) Challenges and Market Headwinds
- The ongoing conflict in the Middle East has caused logistics disruptions, impacting sales in the water business by approximately $10 million in Q1.
- Construction markets remain weak, with expectations for flat performance in the first half of the year.
- DuPont is navigating increased input costs and has implemented pricing actions to offset these pressures, estimating an incremental cost of $90 million for the year.

5) Guidance and Future Outlook
- DuPont raised its full-year 2026 guidance, now expecting net sales of $7.185 billion and adjusted EPS between $2.35 and $2.40.
- For Q2, net sales are projected at $1.8 billion, with operating EBITDA of about $430 million.
- The company anticipates continued organic growth in Healthcare & Water in the mid-single digits and low single digits in Diversified Industrials.
- The transcript lacks specific details on the long-term impacts of the Middle East conflict and further strategic moves in M&A.

Bottom line: DuPont's strong Q1 performance, driven by disciplined execution and strategic initiatives, positions the company well for continued growth despite external challenges. The raised guidance reflects confidence in navigating market headwinds and capitalizing on operational improvements.